Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata and its severe forms are becoming more common, especially among females, adults, and people in the Northeast.

Alopecia areata affects 1 in 50 people, with non-White ethnic groups experiencing the most impact on mental health and work.

One in four people still had symptoms like weight loss, hair loss, and fatigue 12-14 weeks after recovering from COVID-19.

Male pattern hair loss is diagnosed and treated earlier and is milder, possibly due to early puberty.

Scalp cooling can effectively prevent hair loss during chemotherapy, improving patients' quality of life.

The guidelines suggest using various treatments, including antidepressants and steroids, for alopecia areata and discuss the condition's genetic and immune aspects.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

Hidradenitis suppurativa tunnels worsen the disease and often need surgery because current treatments are not very effective.

Emotional symptoms from alopecia areata reduce work productivity and daily activity.

Acne can't be cured but can be managed with treatments like benzoyl peroxide and diet changes; it's costly and can lead to scarring and mental health issues.

Kidney transplant patients who had COVID-19 experienced a significant drop in their quality of life due to long-lasting symptoms.

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

People with hair loss are more likely to have anxiety.

Some people still have COVID-19 symptoms after 90 days, especially older patients and those with severe initial symptoms, but most return to normal.

Improving education, training, and access to affordable treatments is crucial for better managing inflammatory skin diseases in Latin America.

People with androgenetic alopecia often experience more anxiety, depression, and lower self-esteem.

Alopecia areata affects about 1.93% of people worldwide, with more women affected than men.

Melanoma characteristics vary by age, which could help doctors with diagnosis and prevention.

A woman with lupus and severe nerve damage improved with specific treatments.

The Swedish Hairdex-S is a reliable tool for assessing quality of life in Alopecia Areata patients.

Genetic differences affect how people respond to COVID-19.

Turmeric may improve knee osteoarthritis, depression, and metabolic syndrome, but evidence is weak.

Clinical pharmacists are crucial in improving patient safety by reporting medication errors in hospitals.

Kids from areas with more high school dropouts have higher rates of brain injuries.

More pediatric-specific research and guidelines are needed to improve hidradenitis suppurativa treatment in children and adolescents.

People with hidradenitis suppurativa are more likely to have bipolar disorder than those with psoriasis or without skin conditions.

Treating psoriasis on the scalp, nails, and skin folds is challenging, often requiring systemic treatments for severe cases, with some success in topical and biologic treatments.

Oral minoxidil can potentially increase hair growth in people suffering from Central Centrifugal Cicatricial Alopecia.

Young women in West Bengal, India, with PCOS often have estrogen resistance, leptin receptor issues, folate deficiency, T2DM, and acanthosis, commonly linked to obesity.

COVID-19 and hypopituitarism (reduced pituitary gland function) are linked, with the latter's related health issues potentially worsening COVID-19 outcomes, and COVID-19 possibly increasing risk for pituitary complications.